336 related articles for article (PubMed ID: 19149612)
1. Targeted therapies in lung cancer.
Pirker R; Filipits M
Curr Pharm Des; 2009; 15(2):188-206. PubMed ID: 19149612
[TBL] [Abstract][Full Text] [Related]
2. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F
Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956
[TBL] [Abstract][Full Text] [Related]
3. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
Pirker R; Minar W; Filipits M
Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
Filipits M
J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
[TBL] [Abstract][Full Text] [Related]
5. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
6. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
Goss GD; Spaans JN
Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Harichand-Herdt S; Ramalingam SS
Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
[TBL] [Abstract][Full Text] [Related]
8. Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.
Takeda M; Nakagawa K
Curr Cancer Drug Targets; 2015; 15(9):792-802. PubMed ID: 26567882
[TBL] [Abstract][Full Text] [Related]
9. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
Bonomi PD; Gandara D; Hirsch FR; Kerr KM; Obasaju C; Paz-Ares L; Bellomo C; Bradley JD; Bunn PA; Culligan M; Jett JR; Kim ES; Langer CJ; Natale RB; Novello S; Pérol M; Ramalingam SS; Reck M; Reynolds CH; Smit EF; Socinski MA; Spigel DR; Vansteenkiste JF; Wakelee H; Thatcher N
Ann Oncol; 2018 Aug; 29(8):1701-1709. PubMed ID: 29905778
[TBL] [Abstract][Full Text] [Related]
10. Irreversible EGFR inhibitors in the treatment of advanced NSCLC.
Maione P; Rossi A; Bareschino M; Sacco PC; Schettino C; Casaluce F; Sgambato A; Gridelli C
Curr Pharm Des; 2014; 20(24):3894-900. PubMed ID: 24138713
[TBL] [Abstract][Full Text] [Related]
11. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
Chen YM
J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
[TBL] [Abstract][Full Text] [Related]
12. EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis.
Chen P; Wang L; Liu B; Zhang HZ; Liu HC; Zou Z
Eur J Clin Pharmacol; 2011 Mar; 67(3):235-43. PubMed ID: 21207017
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies against EGFR in non-small cell lung cancer.
Pirker R; Filipits M
Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies for advanced non-small cell lung cancer.
Starakis I; Nikolakopoulos A; Mazokopakis EE
Comb Chem High Throughput Screen; 2012 Sep; 15(8):641-55. PubMed ID: 22409867
[TBL] [Abstract][Full Text] [Related]
15. EGFR-directed monoclonal antibodies in non-small cell lung cancer.
Pirker R
Target Oncol; 2013 Mar; 8(1):47-53. PubMed ID: 23300028
[TBL] [Abstract][Full Text] [Related]
16. Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer.
Joy AA; Butts CA
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S24-9. PubMed ID: 19362943
[TBL] [Abstract][Full Text] [Related]
17. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.
Herbst RS; Sandler AB
Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S7-S19. PubMed ID: 15638959
[TBL] [Abstract][Full Text] [Related]
18. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
Pakkala S; Ramalingam SS
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S17-23. PubMed ID: 19362942
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
Sheng Z; Zhang Y
Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
